利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

31 records (took 0.01 seconds)

    METHOD AND COMPOSITION FOR PREVENTING OR ALLEVIATING SYMPTOMS OF MALABSORPTION FROM THE GASTROINTESTINAL TRACT
    3.
    发明申请
    METHOD AND COMPOSITION FOR PREVENTING OR ALLEVIATING SYMPTOMS OF MALABSORPTION FROM THE GASTROINTESTINAL TRACT 审中-公开
    用于预防或消除胃肠道诱发症的症状的方法和组合物

    公开(公告)号：WO2004000340A3

    公开(公告)日：2004-03-25

    申请号：PCT/NL0300455

    申请日：2003-06-20

    Applicant: NUTRICIA NV ,  SPEELMANS GELSKE ,  KNOL JAN ,  GOVERS MARIA JOHANNA ADRIANA P

    Inventor： SPEELMANS GELSKE ,  KNOL JAN ,  GOVERS MARIA JOHANNA ADRIANA P

    IPC: A23L1/03 ,  A23L1/29 ,  A23L1/30 ,  A23L1/308 ,  A61K35/74

    CPC classification number: A61K35/747 ,  A23L33/135 ,  A23L33/40 ,  A23Y2220/73 ,  A23Y2240/75 ,  A23Y2300/55 ,  A23Y2320/29 ,  A61K35/741 ,  A61K35/744 ,  A61K35/745 ,  A61K2300/00

    Abstract: One aspect of the present invention relates to a method of preventing or alleviating symptoms of malabsorption in a monogastric mammal which malabsorption is caused by impaired intestinal digestion, said method comprising the enteral administration to said mammal of an effective amount of one or more strains of the genus Propionibacterium and/or a prebiotic that stimulates gastrointestinal activity of Propionibacterium. Another aspect of the invention relates to a dietary supplement comprising at least 106 metabolically active cells of the genus Propionibacterium; at least 0.5 g of a prebiotic and/or at least 106 metabolically active homofermentative cells of the genus Lactobacillus and/or at least 106 metabolically active cells of the genus Bifidobacterium; and a nutritionally acceptable carrier.

    Abstract translation: 本发明的一个方面涉及一种预防或减轻单胃哺乳动物吸收不良症状的方法，所述单胃哺乳动物由于肠消化受损引起吸收不良，所述方法包括向所述哺乳动物施用有效量的一种或多种 丙酸杆菌属和/或刺激丙酸杆菌的胃肠道活性的益生元。 本发明的另一方面涉及包含丙酸杆菌属的至少106种代谢活性细胞的膳食补充剂; 至少0.5g益生菌和/或至少106种代谢活性的同型发酵细胞和/或至少106种双歧杆菌代谢活性细胞; 和营养可接受的载体。

    CISPLATINUM COMPRISING PHARMACEUTICAL
    9.
    发明申请
    CISPLATINUM COMPRISING PHARMACEUTICAL 审中-公开
    包含药物的CISPLATINUM

    公开(公告)号：WO1998024425A1

    公开(公告)日：1998-06-11

    申请号：PCT/NL1997000661

    申请日：1997-12-03

    Applicant: RIJKSUNIVERSITEIT UTRECHT ,  SEED CAPITAL INVESTMENTS-2 B.V. ,  DE KRUIJFF, Ben ,  SPEELMANS, Gelske ,  STAFFHORST, Rutger, Willibrordus, Hendricus, Maria ,  REEDIJK, Jan

    Inventor： RIJKSUNIVERSITEIT UTRECHT ,  SEED CAPITAL INVESTMENTS-2 B.V.

    IPC: A61K31/28

    CPC classification number: A61K31/685 ,  A61K9/1271 ,  A61K9/1272 ,  A61K31/282 ,  A61K31/555 ,  A61K31/675

    Abstract: A pharmaceutical composition for use in treatment of a subject having neoplasms with a view to reducing size and/or number of neoplasms, said pharmaceutical composition comprising a complex of a cytostatic compound of the cis platinum family and an anionic organic compound as a complexed form of the active pharmaceutical component, said complex having general formula (1) wherein Q = -CO- or -PO(O )-; Y = -CHR'-, -CO-, -PO(O )- or a direct bond; Z1, Z2 = independently O or NR', R1, R2=H or a hydrocarbon group optionally substituted, optionally linked to each other or to R3 and/or R4 wherein R3, R4=H or hydrocarbon group optionally substituted, optionally linked to each other or to R1 and/or R2, wherein R'=H, or a hydrocarbon group optionally substituted and wherein R''=hydrocarbon group substituted by a group capable of liposome formation.

    Abstract translation: 用于治疗具有肿瘤的受试者的药物组合物，以减少肿瘤的大小和/或数量，所述药物组合物包含顺式铂族的细胞抑制化合物和阴离子有机化合物的复合物作为复合形式 所述活性药物组分，所述具有通式（1）的络合物，其中Q = -CO-或-PO（O - ） - ; Y = -CHR'-，-CO-，-PO（O - ） - 或直接键; Z 1，Z 2独立地为O或NR'，R 1，R 2 = H或任选取代的任选取代的烃基，任选地彼此连接或者R 3和/或R 4，其中R 3，R 4 = H或任选取代的烃基， R 1和/或R 2，其中R'= H，或任选取代的烃基，其中R“=被能够形成脂质体的基团取代的烃基。

Patent Agency Ranking